Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | Mexico | Healthcare | Pharmaceuticals | MX$14.87T | 72.2x | 0.61 | MX$14,618 | -4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
J&J | Mexico | Healthcare | Pharmaceuticals | MX$7.48T | 17.1x | -0.45 | MX$3,068 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie | Mexico | Healthcare | Pharmaceuticals | MX$6.03T | 72.4x | -6.02 | MX$3,400.11 | -4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk | Mexico | Healthcare | Pharmaceuticals | MX$5.62T | 18.5x | 0.86 | MX$1,250 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding Participation | Mexico | Healthcare | Pharmaceuticals | MX$4.93T | 25.9x | -0.84 | MX$6,233.57 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis | Mexico | Healthcare | Pharmaceuticals | MX$4.14T | 18.6x | -0.97 | MX$2,235 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Astrazeneca DRC | Mexico | Healthcare | Pharmaceuticals | MX$4.11T | 29.7x | 1.59 | MX$1,343 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck&Co | Mexico | Healthcare | Pharmaceuticals | MX$3.87T | 11.6x | 0 | MX$1,560 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Mexico | Healthcare | Pharmaceuticals | MX$2.94T | 36.4x | -0.96 | MX$5,834.37 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Mexico | Healthcare | Pharmaceuticals | MX$2.57T | 274.5x | -2.94 | MX$1,971.21 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi | Mexico | Healthcare | Pharmaceuticals | MX$2.49T | 20.6x | 6.79 | MX$1,047 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Mexico | Healthcare | Pharmaceuticals | MX$2.48T | 15.6x | 0.05 | MX$440 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Vertex Pharma | Mexico | Healthcare | Pharmaceuticals | MX$2.48T | -246.3x | 2.02 | MX$10,061.90 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol-Myers Squibb | Mexico | Healthcare | Pharmaceuticals | MX$1.97T | -13.8x | 0.05 | MX$980 | -5.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
McKesson | Mexico | Healthcare | Pharmaceuticals | MX$1.72T | 31.8x | -24.28 | MX$13,755 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc DRC | Mexico | Healthcare | Pharmaceuticals | MX$1.42T | 21.2x | -0.43 | MX$711 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bayer | Mexico | Healthcare | Pharmaceuticals | MX$462.97B | -8.9x | -0.61 | MX$492.21 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Teva DRC | Mexico | Healthcare | Pharmaceuticals | MX$308.36B | -11.5x | 0.05 | MX$271 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Grifols Pref | Mexico | Healthcare | Pharmaceuticals | MX$111.51B | 34x | 0.14 | MX$126.63 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bausch Health | Mexico | Healthcare | Pharmaceuticals | MX$33.19B | -34.4x | -0.38 | MX$139 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genomma Lab Int | Mexico | Healthcare | Pharmaceuticals | MX$21.77B | 10.3x | 0.11 | MX$22.27 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 43.7% Upside | Upgrade to Pro+ |